New Agents for the Treatment of Acute Lymphoblastic Leukemia

Herausgegeben:Saha, Vaskar; Kearns, Pamela

• Broschiertes Buch

Produktbeschreibung

It is increasingly recognized that the natural history of cancer formation is a complex path taking many years to develop to a clinically apparent stage in most cases. However, with advancing knowledge comes a whole plethora of questions explored in this book.

Produktdetails

• Verlag: Springer / Springer New York / Springer, Berlin
• Artikelnr. des Verlages: 978-1-4899-8571-2
• 2011
• Seitenzahl: 356
• Erscheinungstermin: 1. Oktober 2014
• Englisch
• Abmessung: 235mm x 155mm x 20mm
• Gewicht: 545g
• ISBN-13: 9781489985712
• ISBN-10: 1489985719
• Artikelnr.: 41620542

Inhaltsangabe

1. The need for new agents - Tim Eden

2. Identifying pre-clinical agents - Shekhar Krishnan, Ashish Masurekar, and Vaskar Saha

3. Pre-clinical evaluation - Barbara Szymanska, Hernan Carol, and Richard Lock

4. Design of early phase trials - James Whitlock and Terzah Horton

5. Strategies for trial design and analyses - Grazia Maria Valsecchi

6. Overview on Molecular and Animal models of ALL - Michael Batey and Josef Vormoor

7. Apoptosis, BCL2 - Guy Makin and Caroline Dive

8. Targeting Stem Cells - Clare Pridans and Brian Huntly

9. Nucleoside Analogues - Pamela Kearns and Vaskar Saha

10. Flt3 Inhibitors - Ronald Stam and Rob Pieters

11. Tyrosine Kinase Inhibitors - Shaun Wilson

12. Monoclonal Antibodies - Arend von Stackelberg

13. Proteasome inhibitors - Joya Chandra and Claudia Miller

14. Targeting epigenetic pathways in ALL - Pamela Kearns

15. Incorporating new therapies in frontline protocols - Paul Gaynon and Theresa Harned